Ivantis Announces Results of Landmark Prospective, Randomized Comparative MIGS Clinical Trial

16 April 2018

International Multi-center Study Compares Effectiveness of the Hydrus® Microstent to Two iStent® Trabecular Micro-Bypass Stents in Standalone Glaucoma WASHINGTON, and IRVINE, Calif., April 16, 2018 /PRNewswire/ — Ivantis Inc., developer of the novel Hydrus® Microstent, a device designed to lower eye pressure for open-angle glaucoma patients, announced today the 12-month results of the COMPARE study for minimally invasive glaucoma surgery […]

Continue Reading

Obsidian Therapeutics Announces $49.5 Million Series A Financing to Develop Controllable Cell and Gene Therapy Products

Financing led by GV to focus on lead programs for next-generation oncology cell therapies Proprietary platform enables installation of pharmacologic operating systems in cell and gene therapy products to provide treating physicians with precise and dynamic control of engineered cells in patients December 06, 2017 06:15 AM Eastern Standard Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Obsidian Therapeutics, Inc., […]

Continue Reading